cenderitide (CD-NP) / Capricor 
Welcome,         Profile    Billing    Logout  
 5 Diseases   0 Trials   0 Trials   72 News 


12»
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Journal:  Targeted Analysis of Mitochondrial Protein Conformations and Interactions by Endogenous ROS-Triggered Cross-Linker Release. (Pubmed Central) -  Oct 30, 2024   
    1718 intra-links reveal dynamic conformations involving chaperones with ATP-dependent conformation cycles, and 385 inter-links reveal dynamic interactions involving OXPHOS complexes and 27 pairs of possible potential interactions. These results signify that R-CDNP can achieve dynamic conformation and interaction analysis of mitochondrial proteins in living cells, thereby contributing to a better understanding of their biological functions.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Review, Journal:  Uptake of Cyclodextrin Nanoparticles by Macrophages is Dependent on Particle Size and Receptor-Mediated Interactions. (Pubmed Central) -  Jan 17, 2024   
    Finally, we investigated the cellular bioavailability of drug-loaded CDNPs using a model anti-inflammatory drug, celastrol, which demonstrated that drug bioactivity is improved by CDNP loading relative to free drug alone. This study thus elucidates the interactions between the polyglucose nanoparticles and macrophages, thereby facilitating their application in macrophage-targeted drug delivery that has applications in the context of tissue injury and repair.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Preclinical, Journal:  Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP. (Pubmed Central) -  Jan 15, 2024   
    There is strong evidence in tuberculosis and in cancer biology that potentiation of the cGAS-STING-IRF3 pathway leads to improved M.tb clearance and also improved antitumor responses in cancer. In addition to the identification of novel inhibitors and their biochemical characterization, we provide proof-of-concept evidence that our E-3 inhibitor potentiates the cGAS-STING-IRF3 pathway in both macrophage cell lines and also in primary human monocyte-derived macrophages.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Journal:  Metal Salts of 4-Chloro-3,5-dinitropyrazole for Promising Eco-Friendly Primary Colors Pyrotechnics. (Pubmed Central) -  Aug 30, 2023   
    In this regard, we present the syntheses of novel green primary colors pyrotechnics (red, green, and blue light-generating pyrotechnics) by employing 4-chloro-3,5-dinitropyrazole (CDNP) as a multifunctional raw material...Chromaticity analysis reveals that the three EMSs possess good color purities of 91, 80, and 70%, respectively. Consequently, the three integrated pyrotechnics exhibit exceptional combustion properties, highlighting their potential for use in various pyrotechnic applications.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Journal:  T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles. (Pubmed Central) -  Feb 11, 2023   
    Using serial magnetic resonance imaging, we identify a radiomic signature in response to CDNP-R848 treatment and ultrasmall superparamagnetic iron oxide (USPIO) imaging reveals that immunosuppressive macrophage recruitment is reduced by CDNP-R848. In conclusion, CDNP-R848 induces tumor regression in experimental glioma by targeting blood-borne macrophages without requiring adaptive immunity.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Journal:  Protective effects of alpha-mangostin encapsulated in cyclodextrin-nanoparticle on cerebral ischemia. (Pubmed Central) -  Nov 22, 2022   
    Combining an in vitro BBB model and a physicochemical binding assay between α-M and albumin, it is speculated that α-M released from CDNP would interact with albumin during its prolonged circulation in the blood, and the resultant α-M/albumin complex may cross the BBB through the absorptive-mediated transcytosis pathway. These findings suggest the potential clinical application of α-M in ischemic stroke treatment.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Journal:  Inhibition of IL-1β release from macrophages targeted with necrosulfonamide-loaded porous nanoparticles. (Pubmed Central) -  Nov 16, 2022   
    Here, we targeted NSA to both mouse and human macrophages by using three different types of porous nanoparticles (NP), i.e. mesoporous silica (MSN), porous crosslinked cyclodextrin carriers (CD-NP), and a mesoporous magnesium-phosphate carrier (MPC-NP), all displaying high loading capacities for this hydrophobic drug...In contrast, MPC-NP completely blocked the metabolic activity in macrophages when loaded with NSA. This study demonstrates the potential of porous nanoparticles for the effective delivery of hydrophobic drugs to macrophages in order to suppress inflammatory responses.
  • ||||||||||  nitroprusside / Generic mfg.
    Nitroprusside based ultramicroporous materials for gas molecule recognition and separation (W181a (McCormick Place Convention Center)) -  Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_8410;    
    Another nitroprusside-based compound, nickel nitroprusside (Ni-NP), with open metal sites (OMS) for the highly efficient separation of propylene from propane under ambient conditions is reported. This material exhibits high C3H6/C3H8 selectivity of 10.5 and an uptake ratio of 1.68, with a remarkable C3H6 uptake capacity.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Injectable polymer-nanoparticle hydrogels enable small molecule drug delivery for local immunotherapy (S105bc (McCormick Place Convention Center)) -  Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_7477;    
    1A), composed of cyclodextrin nanoparticles (CDNPs) dynamically crosslinked by adamantane-modified hyaluronic acid (Ad-HA).Individual components, CDNP and Ad-HA, are viscous solutions that form a viscoelastic hydrogel when mixed (Fig...1E). In sum, the polymer-particle hydrogels developed exhibit sustained release of immunomodulatory drugs and injectable properties that enable their application towards localized immunotherapy.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Novel cyclodextrin-based nanoparticle delivering alpha mangostin to treat brain ischemia (Room 20BCD Theater 5 (San Diego Convention Center)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_11909;    
    Recently, we found that CDNP/MGS decreased infarct volume of brain tissue and deterioration of neurological symptoms in transient middle cerebral artery occlusion model (tMCAO model). In this study, the evidence of presence of MGS in brain tissue, and discuss a mechanism reaching the brain area of CDNP/MGS complex will be discussed.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Journal:  Identification of a Mycobacterium tuberculosis Cyclic Dinucleotide Phosphodiesterase Inhibitor. (Pubmed Central) -  Jun 24, 2021   
    Using a high-throughput assay, we identified six inhibitors of MTB CDN PDE (CdnP). The most potent inhibitor, C82 with an IC of ∼18 μM, did not inhibit the enzymatic activities of three other bacterial CDN PDEs (Yybt, RocR, and GBS-CdnP), a viral CDN PDE (poxin) or mammalian ENPP1.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Journal:  Electrostatically-driven Selective Adsorption of Carbon Dioxide over Acetylene in an Ultramicroporous Material. (Pubmed Central) -  Feb 2, 2021   
    Neutron powder diffraction experiments and molecular simulations reveal that the electrostatic potential compatibility between pore structure and CO 2 allows it to be trapped in a head-on orientation towards the Cd center, whereas the diffusion of C 2 H 2 is electrostatically forbidden. Dynamic breakthrough experiments have validated the separation performance of this compound for CO 2 /C 2 H 2 separation.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  BELIEVE III: CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function (clinicaltrials.gov) -  Jan 4, 2019   
    P1,  N=30, Completed, 
    Our results support further investigations of Cenderitide in HF as a potential future cGMP enhancing therapeutic strategy. Recruiting --> Completed | N=60 --> 30 | Trial completion date: Dec 2016 --> Nov 2018 | Trial primary completion date: Oct 2016 --> May 2018
  • ||||||||||  Journal:  Agents with vasodilator properties in acute heart failure. (Pubmed Central) -  Jun 24, 2018   
    After diuretics, vasodilators are the most common intravenous therapy for AHF, but neither nitrates, nitroprusside, nor nesiritide have robust evidence supporting their ability to provide meaningful effects on clinical outcomes, except perhaps early symptom improvement...These agents include serelaxin, natriuretic peptides (ularitide, cenderitide), β-arrestin-biased angiotensin II type 1 receptor ligands (TRV120027), nitroxyl donors (CXL-1020, CXL-1427), soluble guanylate cyclase modulators (cinaciguat, vericiguat), short-acting calcium channel blockers (clevidipine), and potassium channel activators (nicorandil). No abstract available
  • ||||||||||  ANX-042 / Anexon, cenderitide (CD-NP) / Capricor
    Journal:  Innovative Therapeutics: Designer Natriuretic Peptides. (Pubmed Central) -  May 14, 2017   
    In this review, we report the conceptual framework of peptide engineering of the natriuretic peptides that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension, which include Cenderitide, ANX042 and ZD100.
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Trial completion, Trial primary completion date:  Safety Study of Cenderitide in Stable Chronic Heart Failure (clinicaltrials.gov) -  Feb 1, 2017   
    P2,  N=14, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Trial completion, Trial primary completion date:  Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients (clinicaltrials.gov) -  Aug 30, 2016   
    P1,  N=14, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015 Recruiting --> Completed | Trial primary completion date: Feb 2016 --> May 2016
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Enrollment closed:  Safety Study of Cenderitide in Stable Chronic Heart Failure (clinicaltrials.gov) -  Apr 1, 2015   
    P2,  N=12, Active, not recruiting, 
    Trial primary completion date: Jul 2015 --> Nov 2015 Recruiting --> Active, not recruiting
  • ||||||||||  cenderitide (CD-NP) / Capricor
    Phase classification:  Safety Study of Cenderitide in Stable Chronic Heart Failure (clinicaltrials.gov) -  Mar 11, 2015   
    P2,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting Phase classification: P1/2 --> P2